https://european-biotechnology.net/wp-content/uploads/2026/01/V2-960x540_realistic-scene-with-elderly-care-senior-people.jpeg.webp540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-20 09:27:182026-01-20 09:27:18Heidelberg-based Exciva secures €51M to tackle agitation in Alzheimer’s care
https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-markus-winkler-1430818-30901559.jpg427640Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-19 16:36:482026-01-19 16:36:48AgomAb files for U.S. IPO as fibrosis-focused pipeline moves deeper into the clinic
https://european-biotechnology.net/wp-content/uploads/2026/01/markus-spiske-KTuHfak_EEk-unsplash.jpg427640Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-19 09:03:422026-01-19 09:03:42Genmab and AbbVie’s epcoritamab fails in phase 3 lymphoma study
https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-karola-g-5398881-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-16 16:35:232026-01-16 16:35:23Genethon licenses core AB-1009 technology to AskBio after IND clearance
https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-tara-winstead-8386440-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-16 08:12:232026-01-16 08:12:23EMA and FDA join forces: Aligned principles on AI use in drug development
https://european-biotechnology.net/wp-content/uploads/2026/01/mathieu-stern-1zO4O3Z0UJA-unsplash.jpg427640Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-15 16:54:552026-01-15 16:54:55With a €6.26M round, QLi5 doubles down on proteasome-based ADC payloads
